Article
Cell Biology
Xiang-Yu Gao, Jian Zang, Min-Hua Zheng, Yu-Fei Zhang, Kang-Yi Yue, Xiu-Li Cao, Yuan Cao, Xin-Xin Li, Hua Han, Xiao-Fan Jiang, Liang Liang
Summary: Glioma stem cells formation is promoted by TMZ treatment through upregulation of HMGB1, which activates the TLR2/NEAT1/Wnt pathway, providing a potential therapeutic target for preventing TMZ resistance in GBM patients.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Immunology
Hui Guan, Ming Zhong, Kongyang Ma, Chun Tang, Xiaohua Wang, Muzi Ouyang, Rencai Qin, Jiasi Chen, Enyi Zhu, Ting Zhu, Yongping Lu, Yu Liu, Chengzi Tian, Zhihua Zheng
Summary: This study comprehensively investigated the roles and mechanisms of HMGB1 in different tumors. HMGB1 was found to be differentially expressed in many tumors and normal tissues, and was closely related to tumor burden, drug resistance, and various pathways of tumors. HMGB1 may serve as a novel biomarker for predicting tumor prognosis and efficacy of immune checkpoint inhibitors, and a potential target for anti-tumor therapy.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Correction
Reproductive Biology
Shinichiro Shirouzu, Naohiro Sugita, Narantsog Choijookhuu, Yu Yamaguma, Kanako Takeguchi, Takumi Ishizuka, Mio Tanaka, Kengo Kai, Etsuo Chosa, Yoshihiro Yamashita, Chihiro Koshimoto, Yoshitaka Hishikawa
Summary: An amendment to this paper has been published and is accessible through the original article.
JOURNAL OF OVARIAN RESEARCH
(2023)
Article
Medical Laboratory Technology
Dong Zang, Wen Li, Fan Cheng, Xiaobin Zhang, Ting Rao, Weimin Yu, Jie Wei, Yangyiyan Song, Wanli Jiang
Summary: This study investigated the diagnostic value of HMGB1 levels in patients with acute kidney injury (AKI) caused by sepsis and its relationship with disease prognosis. The results showed that HMGB1 in serum and urine could be used as diagnostic markers for sepsis complicated with AKI, and serum HMGB1 could also be used to assess disease prognosis with good clinical promotion.
CLINICA CHIMICA ACTA
(2022)
Article
Medicine, General & Internal
Linyan Chen, Gaoping Chen, Xiangdong Kong
Summary: This study found that the HMGB1 levels in HD patients are higher than in PD patients, and the levels decrease with HD or PD treatment and are positively correlated with IL-6 and TNF-alpha. Patients with higher HMGB1 levels had more complications but no difference in survival rates. Quality of life was associated with different dialysis methods.
Article
Neurosciences
Wenyang Li, Ming Wang, Wenjia Ma, Ping Liu, Mingming Zhang, Jiarong He, Yan Cui
Summary: This article explores the potential molecular mechanisms of LINC00470 in glioblastoma and reveals that LINC00470 activates the SOX4 gene through the transcription factor EGR2. In addition, Temozolomide treatment can repress glioblastoma progression by inhibiting the LINC00470/EGR2/SOX4 axis.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Hidetaka Morinaga, Yoshimi Muta, Tomoko Tanaka, Makito Tanabe, Yuriko Hamaguchi, Toshihiko Yanase
Summary: HMGB2 plays a crucial role in the early phase of pre-adipocyte and MSC differentiation, affecting the cells' differentiation ability and interaction with other regulators such as PPARg and Wnt/beta-catenin signaling.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Oncology
Junhui Liu, Lun Gao, Xiaonan Zhu, Rongxin Geng, Xiang Tao, Haitao Xu, Zhibiao Chen
Summary: The study revealed that GSDMD expression was upregulated in glioma, significantly associated with WHO grade IV, IDH 1/2 wild-type, and mesenchymal subtypes, as well as shorter overall survival. GSDMD may participate in regulating macrophage infiltration and polarization, serving as a prognostic biomarker and TMZ-treatment response marker in glioma.
Article
Cell Biology
Dylan Jones, Clarissa A. Whitehead, Marija Dinevska, Samuel S. Widodo, Liam M. Furst, Andrew P. Morokoff, Andrew H. Kaye, Katharine J. Drummond, Theo Mantamadiotis, Stanley S. Stylli
Summary: Glioblastoma is a highly invasive and destructive brain tumor, and current standard treatments often fail to effectively eliminate it. In this study, we investigate the effects of several FDA-approved drugs on the invasion and viability of GBM cells. We found that these drugs can reduce cell invasion and viability, suggesting their potential as therapeutic options for GBM.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2023)
Article
Oncology
Hao Shen, Ling Xu, Chunyue You, Huaibo Tang, Haitao Wu, Yong Zhang, Mingxiang Xie
Summary: In this study, miR-665 was found to be downregulated in glioma tissues and cells, and its expression was associated with clinical parameters such as patient survival time and tumor grade. It was revealed that miR-665 could suppress glioma progression by targeting HMGB1 and inhibiting the Wnt/beta-catenin pathway, leading to inhibition of proliferation, migration, and invasion of glioma cells.
Article
Medical Laboratory Technology
Elena Porcu, Francesca Maule, Lorenzo Manfreda, Elena Mariotto, Silvia Bresolin, Alice Cani, Roberta Bortolozzi, Alessandro Della Puppa, Diana Corallo, Giampietro Viola, Elena Rampazzo, Luca Persano
Summary: We found that ANXA2 is a key mediator of the pro-oncogenic features of GBM tumors, involved in stemness, proliferation and invasion, thus affecting patient prognosis. Using the QUADrATiC bioinformatic tool, we identified Homoharringtonine (HHT) as a potent inhibitor of GBM cell motility and proliferation. HHT inhibits a transcriptional program involved in cell migration and invasion by impairing PDGFRα-dependent signaling through STAT3 and RhoA axes. This suggests that HHT could be an effective treatment option for GBM by targeting its hallmarks.
TRANSLATIONAL RESEARCH
(2023)
Editorial Material
Biochemistry & Molecular Biology
Kirit Singh, Kelly M. Hotchkiss, Ian F. Parney, John De Groot, Solmaz Sahebjam, Nader Sanai, Michael Platten, Evanthia Galanis, Michael Lim, Patrick Y. Wen, Giuseppe Minniti, Howard Colman, Timothy F. Cloughesy, Minesh P. Mehta, Marjolein Geurts, Isabel Arrillaga-Romany, Annick Desjardins, Kirk Tanner, Susan Short, David Arons, Elizabeth Duke, Wolfgang Wick, Stephen J. Bagley, David M. Ashley, Priya Kumthekar, Roel Verhaak, Anthony J. Chalmers, Anoop P. Patel, Colin Watts, Peter E. Fecci, Tracy T. Batchelor, Michael Weller, Michael A. Vogelbaum, Matthias Preusser, Mitchel S. Berger, Mustafa Khasraw
Summary: A breakthrough in drug discovery for glioblastoma necessitates the consecutive collection of central nervous system tissue through window of opportunity trials.
Article
Oncology
Hong Shik Yun, Jennifer Lee, Whoon Jong Kil, Tamalee R. Kramp, Philip J. Tofilon, Kevin Camphausen
Summary: AZD0530, a potent small-molecule inhibitor of the Src kinase family, enhances the radiosensitivity of glioblastoma cells and glioblastoma stem-like cells, showing potential as a clinical radiosensitizer for the treatment of glioblastoma.
MOLECULAR CANCER THERAPEUTICS
(2021)
Review
Cell Biology
Sarah Saxena, Veronique Kruys, Raf De Jongh, Joseph Vamecq, Mervyn Maze
Summary: Aseptic surgical trauma induces the release of HMGB1, triggering the immune response and resulting in postoperative cognitive decline.
Article
Immunology
William A. Banks, Kim M. Hansen, Michelle A. Erickson, Fulton T. Crews
Summary: High-mobility group box 1 (HMGB1) is a protein that regulates transcription in the cell nucleus and activates the innate immune system. It can cross the blood-brain barrier (BBB) and affect neuroimmune signaling in the brain and periphery. In this study, the ability of radioactively labeled HMGB1 to cross the BBB was examined. The results showed that HMGB1 could bidirectionally cross the BBB and its transport rates were enhanced by inflammation. This finding suggests that HMGB1 levels have an impact on neuroimmune signaling in various conditions.
BRAIN BEHAVIOR AND IMMUNITY
(2023)
Article
Chemistry, Multidisciplinary
Lin Cai, Ze-Rui Wu, Lei Cao, Jia-Dong Xu, Jiang-Long Lu, Cheng-de Wang, Jing-Hao Jin, Zhe-Bao Wu, Zhi-Peng Su
Summary: ACT001, derived from traditional herbal medicine, has been shown to have effective anticancer activity in clinical trials. This study demonstrated that ACT001 suppressed the growth of pituitary tumor cells and induced autophagic cell death (ACD) through activating JNK and P38 phosphorylation. It suggests that ACT001 may be a novel and effective drug for treating pituitary adenomas.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Chemistry, Multidisciplinary
Zijing Wang, Zhipeng Yang, Jianjuan Jiang, Zhifeng Shi, Ying Mao, Nan Qin, Tiger H. Tao
Summary: A silk fibroin microneedle (SMN) patch designed for glioblastoma (GBM) can bypass the blood-brain barrier and release multiple drugs directly to the tumor site, providing an effective treatment strategy for brain tumors. The biocompatible and biodegradable patch allows for slow drug release over time and can be triggered remotely for rapid drug delivery. In animal models, the patch resulted in decreased tumor volume and increased survival rate, showing potential for clinical treatment of brain tumors.
ADVANCED MATERIALS
(2022)
Article
Cell Biology
Qiu-Yuan Gong, Lin Cai, Yao Jing, Wei Wang, Dian-Xu Yang, Shi-Wen Chen, Heng-Li Tian
Summary: Urolithin A (UA), a natural metabolite, has neuroprotective effects. This study showed that UA decreased brain edema, increased tight junction protein expression, and promoted neuronal autophagy. In addition, UA reduced neuroinflammation by inhibiting two signaling pathways and improved neurological function in mice.
NEURAL REGENERATION RESEARCH
(2022)
Article
Chemistry, Multidisciplinary
Ziyi Jin, Qi Yue, Wenjia Duan, An Sui, Botao Zhao, Yinhui Deng, Yuting Zhai, Yuwen Zhang, Tao Sun, Guang-Ping Zhang, Limei Han, Ying Mao, Jinhua Yu, Xiao-Yong Zhang, Cong Li
Summary: This article reports an intelligent surface-enhanced Raman scattering navigation system that can delineate the acidic margins of gliomas without using exogenous probes. The system uses a homemade deep learning model to process Raman spectra and quickly delineate the pH map of the tumor resection bed. Experimental results demonstrate a significant improvement in overall survival rate of animal models after surgery guided by this system.
Article
Cell Biology
Lin Cai, Qiuyuan Gong, Lin Qi, Tongtong Xu, Qian Suo, Xiang Li, Wei Wang, Yao Jing, Dianxu Yang, Zhiming Xu, Fang Yuan, Yaohui Tang, Guoyuan Yang, Jun Ding, Hao Chen, Hengli Tian
Summary: This study found that ACT001 can alleviate neurodegeneration after TBI by reducing the activation of microglia cells. ACT001 can inhibit the production of pro-inflammatory cytokines induced by LPS, improve cellular apoptosis and tube formation, and its mechanism of action is related to the AKT/NF kappa B/NLRP3 pathway.
CELL COMMUNICATION AND SIGNALING
(2022)
Review
Neurosciences
Rui-Zhe Zheng, Zeng-Xin Qi, Zhe Wang, Ze-Yu Xu, Xue-Hai Wu, Ying Mao
Summary: Significant progress has been made in identifying and managing disorders of consciousness in patients with acquired brain injury. Advanced technology and tools have improved diagnostic accuracy, but there are still challenges in clinical treatment and a lack of effective management protocols.
NEUROSCIENCE BULLETIN
(2023)
Review
Neurosciences
Qiyuan Zhuang, Hui Yang, Ying Mao
Summary: Glioma, the most common and lethal primary brain tumor, is highly heterogeneous and its cell state, including glioma stem cells, microglia, neurons, and immune cells, play crucial roles in tumor initiation, progression, and response to therapy.
NEUROSCIENCE BULLETIN
(2023)
Article
Biochemistry & Molecular Biology
Yifan Yuan, Yang Yu, Yu Guo, Yinghua Chu, Jun Chang, Yicheng Hsu, Patrick Alexander Liebig, Ji Xiong, Wenwen Yu, Danyang Feng, Baofeng Yang, Liang Chen, He Wang, Qi Yue, Ying Mao
Summary: In this study, the diagnostic accuracy of combined CEST and MRS in predicting glioma infiltration was evaluated. The results showed that CEST and MRS were correlated with FET-PET, but the correlation between CEST and MRS was weaker. The combination of CEST/MRS predicted tumor infiltration more accurately than using CEST or MRS alone.
Article
Cell Biology
Wei Wang, Qiu-Yuan Gong, Lin Cai, Yao Jing, Dian-Xu Yang, Fang Yuan, Hao Chen, Heng-Li Tian
Summary: Knockout of SIRT2 gene provides neuroprotection against traumatic brain injury (TBI) by reducing brain edema, inflammation, and improving neurological function. SIRT2 could be a potential novel target for the treatment of TBI.
NEURAL REGENERATION RESEARCH
(2023)
Review
Neurosciences
Lijuan Zhang, Yafei Wang, Taohui Liu, Ying Mao, Bo Peng
Summary: Microglia, as immune cells in the central nervous system, play a crucial role in monitoring the environment and protecting neurons to maintain brain homeostasis. In diseased brains, microglia are important mediators of neuroinflammation and have been extensively studied for their involvement in neurodegeneration. This review summarizes the multifunctional contributions of microglia to homeostasis and their potential as therapeutic targets in neurodegenerative diseases, with a particular focus on microglial replacement therapy.
NEUROSCIENCE BULLETIN
(2023)
Article
Computer Science, Information Systems
Renping Yu, Han Zhang, Xuehai Wu, Xuan Fei, Qing Yang, Zhiwei Ma, Zengxin Qi, Di Zang, Weijun Tang, Ying Mao, Dinggang Shen
Summary: This study aims to predict the outcome of unconscious acquired brain injury patients and differentiate consciousness levels using brain functional imaging and machine learning techniques. The researchers construct functional networks based on resting-state fMRI and use connection strengths as features for outcome prediction and consciousness level differentiation. The study achieves improved classification accuracy for consciousness levels (84.78%) and recovery outcome prediction (89.74%) compared to other methods, and identifies contributive connections across the entire brain. These findings provide potential biomarkers for understanding consciousness and developing diagnostic, prognostic, and therapeutic guidelines for ABI patients.
IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
(2023)
Article
Multidisciplinary Sciences
Fushun Wang, Wei Wang, Simeng Gu, Dan Qi, Nathan A. Smith, Weiguo Peng, Wei Dong, Jiajin Yuan, Binbin Zhao, Ying Mao, Peng Cao, Qing Richard Lu, Lee A. Shapiro, S. Stephen Yi, Erxi Wu, Jason H. Huang
Summary: The researchers discovered two distinct astrocytic Ca2+ signals in the mouse barrel cortex, which play different roles in modulating sensory transmission during sleep and arousal states.
NATURE COMMUNICATIONS
(2023)
Correction
Neurosciences
Lijuan Zhang, Yafei Wang, Taohui Liu, Ying Mao, Bo Peng
NEUROSCIENCE BULLETIN
(2023)
Article
Physics, Multidisciplinary
Andrea Buccellato, Yasir Catal, Patrizia Bisiacchi, Di Zang, Federico Zilio, Zhe Wang, Zengxin Qi, Ruizhe Zheng, Zeyu Xu, Xuehai Wu, Alessandra Del Felice, Ying Mao, Georg Northoff
Summary: In this study, the use of permutation entropy (PE) is proposed to estimate time delays from neural time series, which is a more robust alternative to autocorrelation window (ACW). The validity of this approach is demonstrated on synthetic neural data and hd-EEG human data, suggesting its potential use for characterizing conscious states.
Article
Acoustics
Shaoyuan Yan, Jiajun Shou, Junjin Yu, Jianping Song, Ying Mao, Kailiang Xu
Summary: The study developed an ultrafast ultrasound vector Doppler (ultrafast UVD) method for small vasculature hemodynamic imaging by combining multiangle vector Doppler strategy and ultrafast sequencing. The validity of the technique was demonstrated through experiments on a rotational phantom, rat brain, human brain, and human spinal cord. Compared with the widely accepted accurate flow velocimetry technique ultrasound localization microscopy (ULM), the rat brain experiment showed that the average relative error (ARE) of the velocity magnitude estimated by ultrafast UVD was approximately 16.2%, with a root-mean-square error (RMSE) of the velocity direction of 26.7°. The results demonstrated that ultrafast UVD is a promising tool for accurate blood flow velocity measurement, especially for organs with vasculature typically exhibiting tendential alignment of vascular trees, such as the brain and spinal cord.
IEEE TRANSACTIONS ON ULTRASONICS FERROELECTRICS AND FREQUENCY CONTROL
(2023)
